ClinicalTrials.gov
ClinicalTrials.gov Menu

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03218826
Recruitment Status : Recruiting
First Posted : July 17, 2017
Last Update Posted : February 6, 2019
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in the body or cannot be removed by surgery. PI3Kbeta inhibitor AZD8186 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving PI3Kbeta inhibitor AZD8186 and docetaxel may work better in treating patients with solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Malignant Solid Neoplasm Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Castration-Resistant Prostate Carcinoma HER2/Neu Negative Metastatic Malignant Solid Neoplasm Metastatic Prostate Carcinoma PIK3CB Gene Mutation Progesterone Receptor Negative Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 PTEN Gene Mutation PTEN Loss Stage III Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8 Stage IIIC Prostate Cancer AJCC v8 Stage IV Prostate Cancer AJCC v8 Stage IVA Prostate Cancer AJCC v8 Stage IVB Prostate Cancer AJCC v8 Triple-Negative Breast Carcinoma Unresectable Solid Neoplasm Drug: Docetaxel Other: Laboratory Biomarker Analysis Other: Pharmacological Study Drug: PI3Kbeta Inhibitor AZD8186 Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of PI3Kbeta inhibitor AZD8186 (AZD8186) when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

II. To assess the safety and tolerability of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To assess the objective response rate (ORR) of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

III. To assess the clinical benefit rate at 24 weeks of AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

IV. To investigate a drug-drug interaction between docetaxel and AZD8186 and correlate drug exposure with pharmacodynamics response.

EXPLORATORY OBJECTIVES:

I. Examine the pattern of co-mutated genes in PTEN or PIK3CB mutated tumors and their association with treatment response or resistance.

II. Describe possible mechanisms of acquired resistance to PI3Kbeta inhibition. III. Evaluation of protein expression of the PTEN gene and its association with treatment response or resistance.

IV. Examine isoform-specific AKT inhibition and other downstream target modulation from PI3Kbeta inhibition with AZD8186.

OUTLINE: This is a dose-escalation study of PI3Kbeta inhibitor AZD8186.

Patients receive docetaxel intravenously (IV) over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 orally (PO) twice daily (BID) for 5 days each week. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 3 months.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 58 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Actual Study Start Date : March 16, 2018
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : April 1, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Treatment (docetaxel, PI3Kbeta inhibitor AZD8186)
Patients receive docetaxel IV over 1 hour on day 1 and PI3Kbeta inhibitor AZD8186 PO BID for 5 days each week. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Docetaxel
Given IV
Other Names:
  • Docecad
  • RP56976
  • Taxotere
  • Taxotere Injection Concentrate

Other: Laboratory Biomarker Analysis
Correlative studies

Other: Pharmacological Study
Correlative studies

Drug: PI3Kbeta Inhibitor AZD8186
Given PO
Other Names:
  • AZD-8186
  • AZD8186




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) [ Time Frame: Up to 2 years ]
    Will determine the MTD or RP2D of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

  2. Incidence of adverse events [ Time Frame: Up to 30 days after last dose ]
    Patient safety and tolerability will be described according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version for routine toxicity reporting and CTCAE, version 5 for serious adverse events only. All patients who receive any amount of the study drug will be evaluable for toxicity.


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: At 24 weeks ]
    Will assess the ORR of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors.

  2. Clinical benefit rate (CBR) defined as complete response (CR), partial response (PR), or stable disease assessed by modified Response Evaluation Criteria in Solid Tumors version 1.1 [ Time Frame: At 24 weeks ]
    Will assess the CBR of PI3Kbeta inhibitor AZD8186 when administered in combination with docetaxel in patients with PTEN or PIK3CB mutated advanced solid tumors. A 90% confidence interval on CBR will be calculated assuming binomial proportions.

  3. Drug-drug interaction between docetaxel and PI3Kbeta inhibitor AZD8186 [ Time Frame: Up to 2 years ]
    Will investigate a drug-drug interaction between docetaxel and PI3Kbeta inhibitor AZD8186 and correlate drug exposure with pharmacodynamics response.


Other Outcome Measures:
  1. Co-mutated genes in PTEN or PIK3CB mutated tumors [ Time Frame: Up to 2 years ]
    Will examine the pattern of co-mutated genes in PTEN or PIK3CB mutated tumors and their association with treatment response or resistance. Associations of pre-treatment pattern of co-mutated genes (grouped by pathway for e.g. mutations affecting the PI3K-Akt-mTOR pathway - binary covariate) and response (CR/PR at 6 weeks; binary covariate defining responders and non responders) will be assessed. These associations will be performed using non parametric methods such as the Mann Whitney U test due to the small targeted sample size of this proposed study.

  2. Mechanisms of acquired resistance to PI3Kbeta inhibition [ Time Frame: Up to 2 years ]
    Will describe possible mechanisms of acquired resistance to PI3Kbeta inhibition. Sequencing data from pre- and post-treatment specimens of patients that initially responded to PI3Kbeta inhibitor AZD8186 will be compared to identify newly acquired mutations or deoxyribonucleic acid copy number alterations. Given that the number of patients and recurrence rate of specific events will be low, this analyses will be primarily descriptive with graphical representation in order to uncover any trends such as a pathway specific clustering of resistance mutations or second-site mutations or focal amplifications, that might inform potential mechanisms of acquired resistance. Results will be used to generate future hypotheses that will be tested in larger patient samples.

  3. Protein expression of the PTEN gene [ Time Frame: Up to 2 years ]
    Will evaluation of protein expression of the PTEN gene and its association with treatment response or resistance. Will summarize the expression pattern of PTEN by immunohistochemistry at baseline (archival/pre-treatment specimen) and post-progression on therapy to provide a preliminary assessment on the predictive capacity of this marker in determining responders versus non-responders.

  4. Isoform-specific AKT inhibition [ Time Frame: Up to 2 years ]
    Will examine isoform-specific AKT inhibition and other downstream target modulation from PI3Kbeta inhibition with PI3Kbeta inhibitor AZD8186.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of AZD8186
  • Unlimited prior therapies allowed
  • Docetaxel appropriate

    • Patients who have not received prior docetaxel (or other taxane therapy) in the advanced setting are eligible for all cohorts
    • Patients who have previously received docetaxel (or other taxane therapy) in the advanced setting are eligible for the dose escalation cohort only, if anticipated to have maintained taxane sensitivity and in the opinion of the investigator would still benefit from further docetaxel therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Leukocytes >= 3,000/mcL
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin within normal institutional limits (patients with confirmed Gilbert's syndrome with a total bilirubin =< 2.0 x upper limit of normal [ULN], may be included in this study)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x institutional upper limit of normal
  • Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  • PTEN or PIK3CB mutated advanced solid tumor

    • PTEN loss of function mutation or PIK3CB gain of function mutation identified by local Clinical Laboratory Improvement Act (CLIA) certified next generation sequencing (NGS)
    • Breast cancers patients enrolled on this study must have either:

      • Estrogen receptor positive and HER2 negative breast cancer
      • Triple negative breast cancer
  • Adequate archival tissue (metastatic tissue sample is preferable but primary tumor tissue will be acceptable) or willing to undergo pre-treatment biopsy (for central confirmation of molecular alteration and PTEN immunohistochemical assessment) if adequate archival tissue is unavailable
  • The effects of AZD8186 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of AZD8186 administration
  • Ability to understand and the willingness to sign a written informed consent document
  • DOSE ESCALATION COHORT: Prior receipt of docetaxel is permitted
  • DOSE ESCALATION COHORT: Measurable disease is not required for enrollment
  • PHARMACODYNAMIC EXPANSION COHORT: Prior receipt of docetaxel is not permitted
  • PHARMACODYNAMIC EXPANSION COHORT: Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • PHARMACODYNAMIC EXPANSION COHORT: Consent to allow mandatory paired (pre- and on- treatment) fresh tissue biopsies if deemed safe to do so for quantitation of Akt pathway signaling proteins
  • DISEASE SPECIFIC EXPANSION COHORTS: Prior receipt of docetaxel is not permitted
  • DISEASE SPECIFIC EXPANSION COHORTS: Patients (excepting the prostate cancer patients) must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with CT scan, MRI, or calipers by clinical exam
  • DISEASE SPECIFIC EXPANSION COHORTS: Breast cancers patients enrolled on this study must have:

    • Metastatic or advanced (incurable and unresectable) HER2 negative breast cancer regardless of estrogen receptor status (both hormone receptor positive and triple negative patients are eligible)
    • Received hormonal therapy, as appropriate based on their hormone receptor status; hormone receptor positive patients who have not received endocrine therapy for recurrent/metastatic disease are eligible, permitted their physician feels they are not appropriate for first line endocrine therapy, for example for high risk visceral metastatic disease
  • DISEASE SPECIFIC EXPANSION COHORTS: Prostate cancers patients enrolled on this study (applies to all prostate cancer patients treated on parts 1, 2, and 3) must have:

    • Metastatic or advanced (incurable and unresectable) castration resistant metastatic cancer
    • Received at least one additional line of anti-androgen therapy with abiraterone or enzalutamide
    • Measurable disease is not required for enrollment

Exclusion Criteria:

  • HER2 positive breast cancer
  • Prior treatment with PI3K/AKT inhibitors
  • Any known concurrent RAF or PIK3CA mutation
  • Patients who have had chemotherapy, radiotherapy, immunotherapy or anticancer agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of the first dose of study treatment, except hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with prostate cancer and breast cancer, which are permitted
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)
  • Patients who are receiving any other investigational agents
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AZD8186 or docetaxel or to docetaxel itself
  • Patients receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYP3A4 are ineligible; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference; as part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
  • Existing bleeding or condition associated with increased risk of bleeding
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because AZD8186 is a PI3K inhibitor with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD8186, breastfeeding should be discontinued if the mother is treated with AZD8186; these potential risks may also apply to other agents used in this study
  • Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:

    • A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYP3A4
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
    • A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03218826


Locations
United States, Colorado
University of Colorado Hospital Suspended
Aurora, Colorado, United States, 80045
United States, Maryland
Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting
Baltimore, Maryland, United States, 21287
Contact: Site Public Contact    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Roisin M. Connolly         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Site Public Contact    212-639-7592      
Principal Investigator: Alison M. Schram         
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Site Public Contact    877-312-3961      
Principal Investigator: Ecaterina E. Ileana Dumbrava         
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Alison M Schram JHU Sidney Kimmel Comprehensive Cancer Center LAO

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03218826     History of Changes
Other Study ID Numbers: NCI-2017-01232
NCI-2017-01232 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
18-237
10131 ( Other Identifier: JHU Sidney Kimmel Comprehensive Cancer Center LAO )
10131 ( Other Identifier: CTEP )
UM1CA186691 ( U.S. NIH Grant/Contract )
First Posted: July 17, 2017    Key Record Dates
Last Update Posted: February 6, 2019
Last Verified: January 2019

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Carcinoma
Breast Neoplasms
Prostatic Neoplasms
Neoplasms
Triple Negative Breast Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action